Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Invested CapitalReturn on Sales

Medicure (MCUJF) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Medicure (MCUJF) over the last 17 years, with Q3 2025 value amounting to 12.67%.

  • Medicure's EBITDA Margin rose 49300.0% to 12.67% in Q3 2025 from the same period last year, while for Sep 2025 it was 2.51%, marking a year-over-year decrease of 100800.0%. This contributed to the annual value of 3.13% for FY2024, which is 35700.0% down from last year.
  • According to the latest figures from Q3 2025, Medicure's EBITDA Margin is 12.67%, which was up 49300.0% from 27.26% recorded in Q2 2025.
  • In the past 5 years, Medicure's EBITDA Margin registered a high of 85.73% during Q4 2022, and its lowest value of 33.22% during Q3 2021.
  • For the 5-year period, Medicure's EBITDA Margin averaged around 14.89%, with its median value being 12.63% (2024).
  • Per our database at Business Quant, Medicure's EBITDA Margin plummeted by -1667200bps in 2021 and then soared by 780500bps in 2022.
  • Over the past 5 years, Medicure's EBITDA Margin (Quarter) stood at 46.33% in 2021, then skyrocketed by 85bps to 85.73% in 2022, then crashed by -84bps to 13.62% in 2023, then fell by -8bps to 12.59% in 2024, then increased by 1bps to 12.67% in 2025.
  • Its EBITDA Margin stands at 12.67% for Q3 2025, versus 27.26% for Q2 2025 and 13.11% for Q1 2025.